BERKELEY, CA --(Marketwired - January 11, 2016) - Dynavax Technologies Corporation (
The live or replayed versions of the webcast will be available by visiting the "Investors" section of the Dynavax website or may be reached directly at: http://jpmorgan.metameetings.com/confbook/hea...nk?p=19808
About Dynavax
Dynavax, a clinical-stage biopharmaceutical company, discovers and develops novel vaccines and therapeutics in the areas of infectious and inflammatory diseases and oncology. Dynavax's lead product candidates are HEPLISAV-B™, a Phase 3 investigational adult hepatitis B vaccine and SD-101, an investigational cancer immunotherapeutic currently in several Phase 1/2 studies. For more information, visit www.dynavax.com .
Contact: Michael Ostrach Chief Financial Officer 510-665-7257 Email contact